Global /Canada /Healthcare /Drug Manufacturers - General /MBIO

MindBio Therapeutics Corp.

MBIO

• CSE: MBIO • Delayed

1.00CAD 2%

0.7195 USD

As of 6 June 2026, MindBio Therapeutics Corp. has a market cap of $2.06M USD, ranking #47123 globally and #2443 in Canada. It ranks #4176 in the Healthcare sector, and #1323 in the Drug Manufacturers - General industry.

Global Rank

47123

Country Rank

2443

Sector Rank

4176

Industry Rank

1323

Key Stats

Market Cap

$2.06MUSD

2.88M CAD

Enterprise Value

$6.29MUSD

8.75M CAD

EBITDA (TTM)

-$3.42MUSD

-4.75M CAD

Net Income (TTM)

-$3.94MUSD

-5.49M CAD

PB Ratio

-3.9

Company Profile

Country (HQ)

Canada

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Justin Hanka open_in_new

Founded

2021

Website

mindbiotherapeutics.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
2%	-4%	-24%	-23%	-52%	-23%	-76%	-77%	-97%

News

Markets

Exchange	Ticker	Price	Quotes
Canadian Securities Exchange (CSE) MIC: XCNQ PRIMARY	MBIO ISIN: CA60256C2076 TV: TradingView: CSE: MBIO SA: Stock Analysis: CSE: MBIO YF: Yahoo Finance: MBIO.CN GF: Google Finance: CNSX: MBIO BA: Barron's: MBIO MS: Morningstar: XCNQ: MBIO	1.00 CAD	TV: TradingView: CSE: MBIO SA: Stock Analysis: CSE: MBIO YF: Yahoo Finance: MBIO.CN GF: Google Finance: CNSX: MBIO BA: Barron's: MBIO MS: Morningstar: XCNQ: MBIO
Cboe Canada (NEO) MIC: NEOE	MBIO ISIN: CA60256C2076 TV: TradingView: NEO: MBIO SA: Stock Analysis: NEO: MBIO YF: Yahoo Finance: MBIO.NE GF: Google Finance: NEO: MBIO BA: Barron's: MBIO MS: Morningstar: NEOE: MBIO	1.04 CAD	TV: TradingView: NEO: MBIO SA: Stock Analysis: NEO: MBIO YF: Yahoo Finance: MBIO.NE GF: Google Finance: NEO: MBIO BA: Barron's: MBIO MS: Morningstar: NEOE: MBIO

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About MindBio Therapeutics Corp.

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.

Similar Companies

Industry: Drug Manufacturers - General (Canada)

Name	Market Cap (USD) diff.	PE	Country
Xenon Pharmaceuticals Inc. NASDAQ: XENE	$5.39B 261K%	-	Canada
Knight Therapeutics Inc. TSX: GUD	$519.8M 725.1M CAD 25K%	-	Canada
Milestone Pharmaceuticals Inc. NASDAQ: MIST	$223.22M 11K%	-	Canada
Satellos Bioscience Inc. TSX: MSCL	$155.46M 216.85M CAD 7K%	-	Canada
BioSyent Inc. TSXV: RX	$118.9M 165.86M CAD 6K%	18.5	Canada
Helix BioPharma Corp. TSX: HBP	$110.6M 154.28M CAD 5K%	-	Canada

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 37M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 27M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 17M%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 16M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 14M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 13M%	20.5	Switzerland

chevron_leftBack